Recombinant SARS-CoV-2 Fusion Protein Vaccine

BIOLOGICAL3 trials

Sponsors

Livzon Pharmaceutical Group Inc.

Conditions

COVID-19 PandemicCOVID19

Phase 1

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

CompletedNCT05050474

Livzon Pharmaceutical Group Inc.COVID19

Start: 2021-08-07End: 2022-02-18Updated: 2023-04-25

Phase 2

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

Livzon Pharmaceutical Group Inc.COVID-19 Pandemic

Start: 2021-08-05End: 2022-08-05Updated: 2022-03-03

Unknown Phase

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

Livzon Pharmaceutical Group Inc.COVID-19 Pandemic

Start: 2021-09-30End: 2023-09-30Updated: 2021-11-18